Trump announced on Friday that the US Food and Drug Administration has cleared the emergency use of Remdesivir as a COVID-19 treatment. Gilead Sciences (NASDAQ:GILD) will play a vital role in producing 1.5 million doses for patients across the US suffering critical complications from COVID-19. The now infamous Remdesivir has made headlines over the past month, as speculators look to cash in on the drugs anti-viral capabilities.… Read more
Gilead prepared to surge after FDA approval of COVID-19 treatment Remdesivir
